Project Grant R33CA291199
Award Date 8/1/24
Completion Date 7/31/27
Dollars Obligated $831K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- Summary The National Cancer Institute awarded a $178,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Boston Medical Center Corporation on June 11, 2026, with a completion date of May 31, 2028. This research project aims to develop a cost-effective, scalable methodology to decode the tumor microenvironment (TME) in triple-negative breast cancer (TNBC) by integrating advanced spatial sequencing technologies including spatial Assay for Transposase-Accessible Chromatin...
- Grant Award Summary The National Cancer Institute (NCI) awarded a $450,904 Project Grant to the Pacific Northwest National Laboratory (PNNL), a division of Battelle Memorial Institute, under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. The funded project will develop a novel single-cell (phospho-)proteomics platform designed to characterize tumor microenvironment (TME) components—including cancer cells, immune cells, and stromal...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary The National Cancer Institute awarded $270,683 to the New York Genome Center, Inc. under the Cancer Biology Research program (CFDA 93.396) on May 5, 2026, for development and validation of Paired-Break-Seq, a novel single-cell multiomics sequencing technique. This three-year project, concluding April 30, 2029, will deliver a high-throughput method enabling joint analysis of double-stranded DNA breaks (DSBs), single-stranded DNA breaks (SSBs), and transcriptome...
- The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
- Federal Project Grant Summary New York University School of Medicine received a $703,227 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective June 1, 2026 through May 31, 2031. The project aims to develop ultra-rapid droplet digital PCR (ddPCR) technology and integrated microfluidic devices capable of detecting cancer-driving mutations in tissue samples during surgical procedures. The research addresses...
- Federal Project Grant Award Summary The University of Chicago received a $372,628 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 12, 2025, with completion targeted for August 31, 2028. This award supports research into spatiomolecular profiling of human cancer at scale, specifically focused on developing and advancing spatially resolved transcriptomics (ST) technologies for analyzing tumor...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
- This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
- Federal Grant Award Summary Duke University's Office of Research Administration was awarded $402,135 by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, with completion targeted for April 30, 2029. The project involves the development and optimization of SCHICAR (Single-Cell High-resolution 3D Genome Interactions, Chromatin Accessibility, and transcRiptomes), a novel tri-modal single-cell platform designed to simultaneously capture...